Table 1 Comparison of primary clinical data between the two groups before treatment
From: The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
Groups | Control group | Experimental group | t/χ2 | P |
|---|---|---|---|---|
Age (years) | 55.67 ± 11.46 | 56.21 ± 11.18 | 2.108 | > 0.05 |
Gender (male/female) | 36/24 | 34/26 | 2.725 | > 0.05 |
Course of disease (years) | 9.65 ± 2.55 | 10.04 ± 2.31 | 2.611 | > 0.05 |
BMI (kg/m2) | 25.94 ± 2.51 | 26.13 ± 2.35 | 2.002 | > 0.05 |
HbA1c (%) | 9.36 ± 1.44 | 9.31 ± 1.72 | 2.514 | > 0.05 |
sCr (μmol/L) | 140.21 ± 34.84 | 143.08 ± 36.33 | 2.753 | > 0.05 |
UA (μmol/L) | 366.10 ± 68.54 | 371.40 ± 69.59 | 2.647 | > 0.05 |
uMA/uCr (μg/mg) | 251.52 ± 57.29 | 256.55 ± 58.10 | 2.435 | > 0.05 |
Medications | ||||
Insulin | 54 | 57 | 0.04213 | > 0.05 |
Metformin | 56 | 58 | 0.018 | > 0.05 |
Sulphonylureas | 6 | 4 | 0.3693 | > 0.05 |